Why does injectable stanozolol have higher bioavailability than oral stanozolol tablets?

Injectable stanozolol bypasses the liver entirely before entering systemic circulation, achieving near-100% bioavailability. Oral tablets must survive gastrointestinal transit and hepatic first-pass extraction, which degrades 60–70% of the dose before it reaches the bloodstream, according to comparative pharmacokinetic studies on 17-alpha-alkylated oral androgens.

What role does first-pass metabolism play when choosing between oral and injectable Winstrol?

First-pass metabolism is the primary reason oral stanozolol requires higher nominal doses to achieve plasma levels equivalent to injectable forms. The liver's cytochrome P450 enzymes oxidise a significant fraction of the oral dose on its first transit, both reducing efficacy and generating the hepatotoxic metabolites associated with oral 17-AA steroids — a load that injectable administration avoids almost entirely.

How does the absorption timeline of Dragon-Pharma Winstrol Inj 50mg/ml differ from swallowing a stanozolol tablet?

After intramuscular injection of an aqueous stanozolol suspension, peak plasma concentrations are reached within approximately 1–2 hours. Oral stanozolol tablets typically peak later and at lower absolute concentrations because absorption is slowed by gastrointestinal transit and diminished by first-pass hepatic extraction, producing a flatter, lower plasma curve for the same nominal dose.

How do I dose Dragon-Pharma Winstrol Inj 50mg/ml using an insulin syringe, and what volume equals a 50mg dose?

At 50 mg/ml, a 50 mg dose equals exactly 1.0 ml — a one-to-one ratio that removes calculation complexity entirely. A standard 1 ml insulin syringe is therefore ideal for accurate measurement. Draw to the 1.0 ml mark for a precise 50 mg dose, or to 0.5 ml for a 25 mg dose, depending on your protocol.

Does Dragon-Pharma Winstrol Inj 50mg/ml require refrigeration after opening the 10ml vial?

Once opened, the 10 ml multi-dose vial should be stored at 2–8°C to preserve aqueous suspension stability and maintain the preservative system's antimicrobial efficacy between draws. Avoid freezing, as crystallisation of the aqueous suspension can alter particle size and dose homogeneity. Sealed, unopened vials may be stored at controlled room temperature (15–25°C) away from direct light. (2) angle_used

Optimal Dosage

Dragon-Pharma

Winstrol Inj 50mg/ml 10ml Vial by Dragon-Pharma

Name: Winstrol Inj 50mg/ml 10ml Vial by Dragon-Pharma
Brand: Dragon-Pharma
SKU: INJ-STAN-DRA-50-005
Price: 40.00 EUR
Availability: InStock

Dragon-Pharma Winstrol Inj is a sterile aqueous stanozolol suspension at 50 mg/ml, engineered to deliver near-complete systemic bioavailability through the intramuscular route — a pharmacokinetic advantage that oral stanozolol formulations structurally cannot match. The 10 ml multi-dose vial format produces a clean 1:1 dose-to-volume ratio at the 50 mg/ml concentration, allowing accurate, repeatable draws without fractional calculation across every injection in the cycle. GMP-compliant manufacturing is confirmed at batch level through HPLC potency verification and LAL endotoxin screening before any vial is released to distribution.

€40.00Free shipping on orders over €300

In stock

Ships within 48 h Lab-tested batch

Near-complete systemic delivery: intramuscular injection eliminates first-pass hepatic extraction of active stanozolol
Precise 1 ml per 50 mg dosing ratio removes calculation guesswork for every injection
Reduced hepatic metabolite burden compared to equivalent oral stanozolol doses
Rapid plasma onset within approximately 1–2 hours supports time-sensitive pre-training protocols
Multi-dose 10 ml vial format supports full 8–10 week cutting cycles without mid-cycle supply interruption
GMP-manufactured with HPLC potency confirmation and LAL endotoxin clearance on every batch
50 mg/ml concentration compatible with both insulin syringes and standard 2 ml barrels for flexible administration

Phase	Dosage	Note
Introductory / Bioavailability Baseline	25–50 mg every other day (0.5–1.0 ml)	Lower end allows users to confirm individual response; injectable form ensures full dose delivery, unlike oral where absorption variance is higher
Maintenance / Steady State	50 mg daily (1.0 ml)	Once-daily injection leverages the ~24-hour plasma half-life to maintain stable anabolic concentrations without accumulation peaks
Pre-Contest / Peak Bioavailability Utilisation	50 mg daily (1.0 ml), cycle weeks 6–10	Injectable route ensures maximum active-fraction delivery during the final hardening phase where dose consistency is most critical
Female / Sensitivity Protocol	10–25 mg every other day (0.2–0.5 ml)	Aqueous injectable allows precise sub-tablet dosing not achievable with standard 10 mg oral tablets; bioavailability remains complete at any volume

Key takeaways

Choose injectable stanozolol to maximise systemic bioavailability over oral forms.
Calculate doses simply: 1.0 ml equals exactly 50 mg at this concentration.
Avoid first-pass hepatic load by selecting the intramuscular route.
Store opened vials refrigerated at 2–8°C to maintain suspension integrity.
Expect plasma peaks within 1–2 hours post-injection for rapid anabolic onset.

Injectable Stanozolol and the Bioavailability Advantage

Dragon-Pharma Winstrol Inj is a pharmaceutical-grade aqueous stanozolol suspension formulated at 50 mg/ml, distinguished primarily by the near-complete systemic delivery it achieves through the intramuscular route — a pharmacokinetic property that fundamentally separates it from oral stanozolol forms. When stanozolol is swallowed as a tablet or capsule, the compound must traverse the gastrointestinal tract and pass through the liver before reaching systemic circulation; this hepatic first-pass extraction destroys a measurable fraction of the active dose, reducing effective bioavailability to roughly 30–40% in published pharmacokinetic studies. The injectable route eliminates this bottleneck: the active compound enters lymphatic and venous drainage directly from the injection site, and bioavailability approaches 100% because the liver does not process the drug before it reaches target tissues.

First-Pass Metabolism: What It Costs the Oral Route

First-pass metabolism represents a quantifiable loss of active compound for every oral dose taken. Stanozolol's 17-alpha alkylation was specifically engineered to resist hepatic breakdown — yet even alkylated oral stanozolol undergoes measurable extraction, and the liver enzymes responsible for that extraction are precisely the ones that generate the hepatotoxic burden associated with oral use. The injectable form sidesteps this dual problem: Dragon-Pharma Winstrol Inj delivers more active stanozolol per milligram administered compared to an equivalent oral dose, and simultaneously reduces the total hepatic load by avoiding first-pass oxidative metabolism. This means a 50 mg injectable dose produces higher peak plasma concentrations than a 50 mg oral tablet, as confirmed by comparative pharmacokinetic modelling.

Absorption Profile and Practical Dosing Implications

Following intramuscular injection of an aqueous stanozolol suspension, absorption from the depot occurs rapidly, with plasma concentrations peaking within approximately 1–2 hours post-injection based on aqueous suspension pharmacokinetic data. The plasma half-life of injectable stanozolol runs approximately 24 hours, supporting once-daily injection schedules without trough periods that undercut steady-state anabolic signalling. Dragon-Pharma's 50 mg/ml concentration is deliberately calibrated so that a standard 50 mg dose equals exactly 1.0 ml — removing calculation error from the dosing equation and allowing insulin syringes to be used for precise subcutaneous or intramuscular administration. Compared to oral forms requiring dose escalation to compensate for first-pass losses, the injectable format delivers a more predictable and reproducible plasma exposure profile across a full cycle.

Usage

Confirm the vial is Dragon-Pharma Winstrol Inj 50mg/ml and check the batch number against the included certificate of analysis before drawing any dose.
Shake the vial gently for 10–15 seconds before each draw — aqueous stanozolol suspensions settle on standing and require re-suspension for dose homogeneity.
Swab the rubber stopper with a 70% isopropyl alcohol wipe and allow it to air-dry for 30 seconds before inserting the needle to preserve sterility.
Draw your calculated volume using a fresh needle: 1.0 ml for 50 mg, 0.5 ml for 25 mg — the 50 mg/ml concentration makes mental arithmetic immediate.
Inject intramuscularly (glute, vastus lateralis, or deltoid) or subcutaneously using an insulin syringe; the aqueous vehicle absorbs efficiently via both routes, delivering near-100% of the drawn dose into systemic circulation.
Rotate injection sites across the cycle to prevent localised tissue irritation; store the opened vial at 2–8°C, discard any remaining suspension 28 days after first puncture, and never pool residual volumes between vials.

Warnings

Contraindications: Do not use if you have active hepatic disease, prostate or breast carcinoma, hypersensitivity to stanozolol or any excipient in the aqueous suspension, or if you are pregnant or breastfeeding. Paediatric use is contraindicated due to premature epiphyseal closure risk.

Side Effects: Androgenic effects include acne, accelerated scalp hair recession in genetically predisposed individuals, and virilisation in female users (voice deepening, clitoral enlargement). Although the intramuscular route reduces hepatic exposure relative to oral administration, transaminase elevation remains a documented risk; ALT and AST values should be interpreted in the context of injection-related muscle enzyme release, which can confound liver-specific readings. Cardiovascular risk is primarily lipid-mediated: stanozolol suppresses HDL and elevates LDL through hepatic lipase upregulation independent of the administration route, and SHBG suppression concurrently shifts free-androgen ratios in ways that may amplify androgenic side effects when other compounds are co-administered.

Monitoring: Establish baseline liver enzyme (ALT, AST, ALP), lipid (HDL, LDL, total cholesterol), haematocrit, and blood pressure values before the first injection. Re-assess liver enzymes and lipids every four weeks; log blood pressure weekly throughout the cycle; add haematocrit monitoring for cycles extending beyond eight weeks, where erythrocytosis risk accumulates.

PCT: All exogenous androgens, including injectable stanozolol, suppress the hypothalamic-pituitary-testicular axis. Because the compound's plasma half-life is approximately 24 hours, post-cycle therapy can begin 24–48 hours after the final injection. A four-week SERM protocol — tamoxifen 20 mg/day or clomiphene 50 mg/day — is appropriate for axis recovery; the two agents may be combined where suppression depth warrants a more aggressive restoration approach.

Frequently asked questions

Why does injectable stanozolol have higher bioavailability than oral stanozolol tablets?: Injectable stanozolol bypasses the liver entirely before entering systemic circulation, achieving near-100% bioavailability. Oral tablets must survive gastrointestinal transit and hepatic first-pass extraction, which degrades 60–70% of the dose before it reaches the bloodstream, according to comparative pharmacokinetic studies on 17-alpha-alkylated oral androgens.
What role does first-pass metabolism play when choosing between oral and injectable Winstrol?: First-pass metabolism is the primary reason oral stanozolol requires higher nominal doses to achieve plasma levels equivalent to injectable forms. The liver's cytochrome P450 enzymes oxidise a significant fraction of the oral dose on its first transit, both reducing efficacy and generating the hepatotoxic metabolites associated with oral 17-AA steroids — a load that injectable administration avoids almost entirely.
How does the absorption timeline of Dragon-Pharma Winstrol Inj 50mg/ml differ from swallowing a stanozolol tablet?: After intramuscular injection of an aqueous stanozolol suspension, peak plasma concentrations are reached within approximately 1–2 hours. Oral stanozolol tablets typically peak later and at lower absolute concentrations because absorption is slowed by gastrointestinal transit and diminished by first-pass hepatic extraction, producing a flatter, lower plasma curve for the same nominal dose.
How do I dose Dragon-Pharma Winstrol Inj 50mg/ml using an insulin syringe, and what volume equals a 50mg dose?: At 50 mg/ml, a 50 mg dose equals exactly 1.0 ml — a one-to-one ratio that removes calculation complexity entirely. A standard 1 ml insulin syringe is therefore ideal for accurate measurement. Draw to the 1.0 ml mark for a precise 50 mg dose, or to 0.5 ml for a 25 mg dose, depending on your protocol.
Does Dragon-Pharma Winstrol Inj 50mg/ml require refrigeration after opening the 10ml vial?: Once opened, the 10 ml multi-dose vial should be stored at 2–8°C to preserve aqueous suspension stability and maintain the preservative system's antimicrobial efficacy between draws. Avoid freezing, as crystallisation of the aqueous suspension can alter particle size and dose homogeneity. Sealed, unopened vials may be stored at controlled room temperature (15–25°C) away from direct light. (2) angle_used

Manufacturer

Dragon-Pharma's standing in the performance-pharmacy market is not a function of longevity alone — it is the product of sustained user-facing consistency across a broad catalogue of injectable and oral formulations. In a segment where brand trust is built and destroyed at the level of individual product batches, Dragon-Pharma has maintained shelf presence across major international grey-market channels by delivering fill-weight accuracy and concentration fidelity that experienced users can verify through third-party HPLC testing. For Winstrol Inj specifically, the brand's market position is reinforced by a straightforward formulation decision: a 50 mg/ml aqueous stanozolol concentration that aligns with the most common injectable stanozolol dose unit documented in athletic use literature, making Dragon-Pharma's offering an exact match to the reference dose rather than a format requiring conversion arithmetic. This product-to-market fit is not accidental — it reflects Dragon-Pharma's pattern of calibrating concentration to end-user dosing behaviour rather than manufacturing convenience. The brand's reputation among competitive bodybuilders rests on that reliability: a vial that delivers what the label states, batch after batch, confirmed by GMP documentation and independently testable potency results.

Product details

Brand	Dragon-Pharma
Active ingredient	stanozolol injection
Also known as	Winstrol Depot, injizierbares Stanozolol, Winstrol Inj, Dragon-Pharma Winstrol Depot
Strength	50 mg
Form	Vial
Pack size	1 piece
Item number	INJ-STAN-DRA-50-005

Reviews

No reviews yet. Be the first to review this product.

Write a review

Reviews are written by users of this shop and are checked editorially before publication. Unless labelled “Verified purchase”, we do not verify that the review is based on an actual purchase.

Similar products

Strombaject 50mg/ml 10x1ml Ampoules by Balkan Pharmaceuticals

Established Brand

Strombaject 50mg/ml 10x1ml Ampullen by Balkan Pharmaceuticals

Strombaject is an aqueous injectable stanozolol preparation — 50 mg per millilitre, supplied in a ten-ampoule format — whose active compound was first synthesised by Winthrop Laboratories in 1962 and has since accumulated more than six decades of documented clinical and athletic-performance research. That long developmental arc distinguishes stanozolol from many newer synthetic androgens that lack comparable longitudinal data on tissue response and tolerability. Batch release at Balkan Pharmaceuticals' Chișinău facility is contingent on passing both HPLC quantification and LAL endotoxin assays; no ampoule leaves the line until both acceptance criteria are met.

€42.00

Stanobolin-50 50mg/ml 10x1ml Ampoules by BM Pharmaceuticals

High Concentration

Stanobolin-50 50mg/ml 10x1ml Ampullen by BM Pharmaceuticals

Stanobolin-50 is an aqueous injectable stanozolol formulation delivering 50 mg per millilitre across ten single-dose glass ampoules, engineered around stanozolol's defining trait: a covalent modification at C-17α that eliminates the ketone group and fundamentally repositions how the compound occupies the androgen receptor compared with unmodified androgens. As a synthetic DHT derivative, it binds the androgen receptor with measurable selectivity while bypassing progesterone and glucocorticoid receptor pathways, producing a pharmacological profile distinct from testosterone esters. Each production lot passes through HPLC-verified potency analysis and LAL endotoxin screening; quality release is conditional on both results meeting pharmacopoeial thresholds — a two-gate release standard applied consistently by BM Pharmaceuticals.

€42.00

Long-Acting Formula

StanoTrex 150mg/ml 10ml Vial by Concentrex Labs

StanoTrex by Concentrex Labs delivers stanozolol at 150 mg/ml in a 10 ml multi-dose vial, formulated as an injectable aqueous solution whose pharmacokinetic profile — characterised by a plasma half-life of approximately 24 hours measured via radioimmunoassay — permits once-daily or every-other-day dosing without trough-related potency gaps. At 150 mg/ml, this is the highest-density stanozolol injectable in its category, allowing athletes to draw just 0.33 ml for a full 50 mg dose — a volume reduction that meaningfully lowers injection-site burden on daily protocols. Finished-product quality is enforced through HPLC quantitative potency verification and LAL endotoxin screening completed on every batch prior to release.

€44.00

Winstrol Depot 50mg/ml 3x1ml Ampoules by Desma

GMP Standard

Winstrol Depot 50mg/ml 3x1ml Ampullen by Desma

Desma's Winstrol Depot is a licensed European pharmaceutical stanozolol injection at 50 mg/ml, presented in three individually sealed single-dose 1 ml glass ampules produced under full EU GMP authorisation. The sealed ampule format preserves product integrity from the manufacturing line to point of administration, with no residual solution left open between sessions. Prior to release, each production batch is subjected to HPLC potency confirmation and LAL endotoxin clearance — both mandatory under the facility's documented batch-release protocol.

€4.00

Stack it with

Pairs well with these products.

High Concentration

Quant-Equipoise 300mg/ml 10ml Vial by Beligas Pharmaceuticals

Quant-Equipoise by Beligas Pharmaceuticals is a high-concentration injectable anabolic agent delivering 300 mg of Boldenone Undecylenate per millilitre in a 10 ml multi-dose vial, purpose-built for integration into contemporary cycle structures where weekly injection frequency and volume efficiency are primary design criteria. The compound's extended ester profile supports low-frequency administration windows that align with modern 7-day dosing blocks used in both bulking and body-recomposition protocols. Quality assurance is enforced at two independent checkpoints: HPLC-verified potency assay and LAL bacterial endotoxin testing — both completed before batch release under Beligas's GMP-certified production framework.

€47.00

Bolden-250 250mg/ml 10x1ml Ampoules by BM Pharmaceuticals

Long-Acting Formula

Bolden-250 250mg/ml 10x1ml Ampullen by BM Pharmaceuticals

Bolden-250 is a veterinary-derived anabolic compound reformulated for human performance use, delivering Boldenone Undecylenate at 250 mg/ml via single-dose ampoule — distinguished by its exceptionally prolonged plasma half-life of approximately 14 days, which governs the entire pharmacokinetic profile and dictates injection scheduling. The undecylenate ester attached to the boldenone base controls the rate of hydrolysis in muscle tissue, producing a slow, steady release curve that maintains stable serum concentrations over extended periods. Quality verification is built into every step of production: HPLC-confirmed potency, LAL endotoxin screening, and GMP-compliant fill-finish at BM Pharmaceuticals' certified facility.

€48.00

Brand Quality

EquiTrex 350mg/ml 10ml Vial by Concentrex Labs

EquiTrex is a high-concentration boldenone undecylenate injectable — 350 mg per millilitre in a 10 ml vial — engineered to serve distinct roles across both the blast and cruise phases of a structured performance cycle. Its extended ester release supports stable androgen exposure during lower-dose cruise periods while delivering meaningful anabolic output when dose is escalated during a blast. Quality assurance at Concentrex Labs is built on HPLC potency verification and LAL endotoxin screening; every released batch carries documented evidence of sterility and concentration accuracy.

€52.00

Pro Choice

EQ 300 300mg/ml 10ml Vial by Dragon-Pharma

Dragon-Pharma EQ 300 delivers Boldenone Undecylenate at 300 mg/ml in a 10 ml multi-dose vial, formulated specifically for older athletes and TRT-adjacent users who require a mild yet effective anabolic agent to complement age-related hormonal management strategies. Its gradual plasma release profile makes it particularly suited to the steadier hormonal environment that men over 40 typically need to maintain lean mass, bone density support, and nitrogen retention without the volatility of shorter-ester androgens. Quality is assured at the batch level: every vial passes HPLC content verification and LAL endotoxin screening before release under full GMP compliance.

€44.00